The relative lower prevalence of somatic TP53 mutation in AML compared to solid tumors like ovarian (48%), and colorectal (43%) suggests that other cooperating events are necessary for leukemic progression [3]. This evidence concerns the gene TP53 and acute myeloid leukemia.